Provided by Tiger Trade Technology Pte. Ltd.

Tyra Biosciences, Inc.

22.01
-4.7200-17.66%
Pre-market: 21.71-0.3000-1.36%05:13 EDT
Volume:6.07M
Turnover:125.26M
Market Cap:1.31B
PE:-9.16
High:22.30
Open:18.94
Low:18.66
Close:26.73
52wk High:40.65
52wk Low:11.70
Shares:59.49M
Float Shares:35.21M
Volume Ratio:6.57
T/O Rate:17.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4031
EPS(LYR):-2.0125
ROE:-45.31%
ROA:-28.46%
PB:3.70
PE(LYR):-10.94

Loading ...

Tyra Biosciences price target lowered to $30 from $45 at H.C. Wainwright

TIPRANKS
·
16 mins ago

U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs

Reuters
·
16 hours ago

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Dow Jones
·
Yesterday

Tyra Biosciences Shares Sink After Bladder-Cancer Treatment Causes Adverse Events in Some Patients During Clinical Trial

Dow Jones
·
Yesterday

U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software

Reuters
·
Yesterday

Tyra Biosciences Tumbles After Cancer Drug Misses Wall Street Expectations

Reuters
·
Yesterday

Tyra Biosciences Reports 79% Response Rate in Phase 2 Bladder Cancer Study of Dabogratinib at 60 Mg Dose

Reuters
·
Yesterday

Tyra Biosciences, - Announces Initial Phase 2 Surf302 Results for Oral Dabogratinib

THOMSON REUTERS
·
Yesterday

Tyra Biosciences to Present at Cantor Global Healthcare Conference 2026

Reuters
·
Yesterday

Analysts Are Bullish on Top Healthcare Stocks: Intuitive Surgical (ISRG), Tyra Bioscience (TYRA)

TIPRANKS
·
Sep 08

U.S. Small Caps Close Up; Tyra Biosciences Climbs Highest

Dow Jones
·
Sep 05

Tyra Biosciences Price Target Maintained with a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 05

Tyra Biosciences: Buy Rating Reiterated as SURF302 Data Upside Beckons; 12‑Month Price Target Maintained at $45

TIPRANKS
·
Sep 04

Tyra Biosciences to Present Initial Phase 2 Surf302 Data for Oral Dabogratinib in Intermediate-Risk Bladder Cancer on Sept. 9

Reuters
·
Sep 04

Tyra Bioscience (TYRA) Gets a Buy from Bank of America Securities

TIPRANKS
·
Aug 11

BofA Adjusts Price Target on Tyra Bioscience to $39 From $42

MT Newswires Live
·
Aug 11

Climb Bio Q2 Net Loss Widens on Pipeline Advancement

Reuters
·
Aug 06

Enliven Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 06

Tyra Biosciences price target lowered to $42 from $44 at Jefferies

TIPRANKS
·
Aug 06

Tyra Biosciences delayed cancer data by one month, says JonesResearch

TIPRANKS
·
Aug 06